A cluster‑randomized clinical trial published in The BMJ found that an AI‑driven clinical decision support system (CDSS) significantly improved quality of care and long‑term outcomes for acute ischemic stroke patients. The multi‑center study in China reported adherence gains to guideline‑recommended therapies and improvements in functional outcomes at follow‑up. Investigators attributed benefits to real‑time recommendations embedded in workflows that supported thrombolysis decisions, secondary prevention, and rehabilitation planning. The trial underscores practical gains when AI tools are integrated into clinician workflows and evaluated in randomized, implementation‑focused designs. The results provide a template for regulatory and payer conversations about clinical utility and reimbursement for AI decision tools in acute care pathways.